½ÉÆò¿øÀº '¾ÏȯÀÚ¿¡°Ô ó¹æ.Åõ¿©ÇÏ´Â ¾àÁ¦¿¡ ´ëÇÑ ¿ä¾ç±Þ¿©ÀÇ Àû¿ë±âÁØ ¹× ¹æ¹ý¿¡ °üÇÑ ¼¼ºÎ»çÇ×À» °³Á¤ °ø°íÇÑ ¹Ù, À̸¦ ¾È³»ÇØ µå¸³´Ï´Ù.
¾Æ¿ï·¯, µ¿ »çÇ×Àº ½ÉÆò¿ø ȨÆäÀÌÁö (ÀÇ·áÁ¤º¸-ÀǾàÇ°Á¤º¸-¾ÏÁúȯ»ç¿ë¾àÁ¦ ¹× ¿ä¹ý-°ø°í)¿¡ °ÔÀçµÇ¾î ÀÖÀ¸´Ï Âü°íÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
== ´Ù À½ ==
1) ½Å¼³
- Á÷°áÀå¾Ï¿¡ ‘irinotecan + leucovorin + (infusional) fluorouracil (FOLFIRI) + aflibercept’ º´¿ë¿ä¹ý (2Â÷, °í½ÄÀû¿ä¹ý)
- À¯¹æ¾Ï¿¡ ‘FEC(fluorouracil + epirubicin + cyclophosphamide) → pertuzumab + trastuzumab(IV, SC) + docetaxel' º´¿ë¿ä¹ý (¼±ÇàÈÇпä¹ý)
- À¯¹æ¾Ï¿¡ ‘pertuzumab + trastuzumab(IV, SC) + docetaxel + carboplatin' º´¿ë¿ä¹ý (¼±ÇàÈÇпä¹ý)
- À¯¹æ¾Ï¿¡ ‘pertuzumab + trastuzumab(IV, SC) + docetaxel' º´¿ë¿ä¹ý (¼±ÇàÈÇпä¹ý)
- À¯¹æ¾Ï¿¡ ‘pertuzumab + trastuzumab(IV, SC) + docetaxel' º´¿ë¿ä¹ý (1Â÷, °í½ÄÀû¿ä¹ý)
2) º¯°æ
- À¯¹æ¾Ï¿¡ 'trastuzumab(IV, SC) + docetaxel' º´¿ë¿ä¹ý (1Â÷, °í½ÄÀû¿ë¹ý)
@½ÃÇàÀÏ : 2017³â 6¿ù 01ÀÏ
÷ºÎ : °³Á¤¾È 2ºÎ